bluuebunny/crossref_metadata_2025_split huggingface dataset:
Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM): BMT CTN0702-stamina (NCT01109004).
Authors: Somlo George , Pasquini Marcelo C. , Blackwell Beth , Devine Steven Michael , Ganguly Siddhartha , Efebera Yvonne , Giralt Sergio , Hari Parameswaran , Koreth John , Landau Heather Jolie , McClune Brian L. , Quazilbash Mussafar , McCarthy Philip L. , Shah Nina , Vesole David H. , Vij Ravi , Vogl Dan T. , Krishnan Amrita Y. , Stadtmauer Edward A. , Geller Nancy 
Published: September 2018

8010 Background: The Stamina trial primarily aimed to identify the best strategy among AM, ACM, and TAM, leading to longer PFS (LBA-1, ASH, 2016). Here we report on interim, exploratory results of the association between PFS and overall survival (OS) and baseline MM response, risk category, and treatments (Rx). Methods: Pts with MM, < 71 years, < 12 mos from diagnosis were randomized to melphalan 200mg/m2(mel) and AHCT (AM), tandem mel AHCT (TAM), or mel AHCT and 4 cycles of RVD ((ACM). Pts received Len till progression. Pts were stratified by high risk vs. standard ( del13q, del17q, t(4;14), t(14;16), t(14;20) and hypodyploid; high β2 microglobulin). Kaplan Meier estimates of PFS and OS were performed as a function of Rx and ≥ very good partial response (VPGR including CRs) vs. < VGPR. Cox proportional hazard models explored associations between PFS or OS and risk category, Rx, and ≥ VPGR vs. < VGPR. Results: Between 6/2010-11/2013, 758 pts (AM, N = 257; ACM, N = 254; TAM, N = 247) aged 20-70 years (median 57y) were enrolled (24% high-risk). Baseline ≥VGPR responses were 45.5- 49.8%. PFS at 38 months was similar. For < VGPR, 38-mos PFS with TAM:55.8% (95%CI: 45.8%, 64.7%); ACM: 54.0% (44.7%, 62.5%); AM: 50.1% (40.6%, 58.9%); For ≥VGPR, 38-mos PFS with TAM: 57.1% (46.8%, 66.1%); ACM: 60.1% (50.1%, 68.7%); AM: 55.1% (45.1%, 64.0%). Analyzing response, risk category, and Rx revealed no association between baseline response and PFS (Baseline response < VGPR, hazard ratio (HR): 1.21,95% CI: 0.97-1.52) or OS (baseline response < VGPR, HR 1.02, 95%CI:0.70-1.48). High risk category had an adverse association for PFS (HR 1.62, 95% CI: 1.27-2.07) and OS (HR 1.51 (95% CI:1.01-2.26). Conclusions: In this analysis < VGPR at baseline was not associated with PFS or OS. High-risk had an adverse association. Whether accomplishment of CR/minimal residual disease after AM, ACM,or TAM predicts for longer PFS and OS is the subject of ongoing analysis. Clinical trial information: NCT01109004.
Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.
Authors: Dhakal Binod , D'souza Anita , Hamadani Mehdi , Arce-Lara Carlos Eduardo , Schroeder Katrina , Gauger Katelyn , Crone Karen , Pasquini Marcelo C. , Chhabra Saurabh , Hari Parameswaran 
Published: September 2018

8012 Background: Bendamustine has promising activity in RRMM. This phase I (NCT02477215) study assessed the overall safety and activity of the combination of bendamustine with ixazomib & dexamethasone in pts. with MM pts. refractory to proteasome inhibitors and IMIDs. Methods: Design: Open label dose escalation (3+ 3 design) Doses: Bendamustine at escalating doses of 70, 80 and 90 mg/m2 on days 1,2 of each cycle with weekly ixazomib (4mg) and dexamethasone (40 mg) on days 1,8, 15 in 28-day cycles for up to 8 cycles in responders and 4 cycles if no anti-MM response. Primary end point was safety, maximum tolerated dose (MTD) and the recommended phase II (RP2D) dose. Results: As of Jan 2017, the phase I portion is complete (N= 15). The median age was 67 years with 5 (range: 2-10) median number of prior therapies. Prior therapies included bortezomib (100%), lenalidomide (100%), carfilzomib (47%), oprozomib (7%), thalidomide (7%), pomalidomide (7%) and 87% autotransplant. Five (33%) pts. completed their planned courses of therapy (4 or 8 cycles) and 3 (20%) continued on active therapy. Seven (47%) pts. discontinued study treatment (6 related to disease progression). Grade 3/ 4 adverse events were: lymphopenia (67%), neutropenia (27%), thrombocytopenia (33%), decreased WBC counts (13%), hematuria (7%), diarrhea (7%), anemia (7%), lung infection (7%), and skin ulceration (7%). Three (20%) pts. died of myeloma progression. In dose cohort 3 (bendamustine 90 mg/m2), 2 /6 pts. developed hematologic DLTs (neutropenia and thrombocytopenia) meeting MTD; RP2D was determined to be 80 mg/m2. The table below shows responses among pts receiving at least 2 cycles. The median duration of response was not reached at median follow up of 8 months (range, 4-13+) in responders. Conclusions: BID has an acceptable safety profile and a promising ORR of 45% and CBR of 73% in pts. with advanced double refractory MM. Clinical trial information: NCT02477215. [Table: see text]
Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM).
Authors: Alsaid Nimer , McBride Ali , Agarwal Amit Balkrishna , Mutairi Abdulaali , Anwer Faiz , Abraham Ivo 
Published: September 2018

8030 Background: CAR, IXA, ELO, and DAR in triplet combination with LEN+DEX have shown superior efficacy over LEN+DEX in R/R MM, but their comparative efficacy and cost effectiveness has not been estimated. Methods: Network meta-analysis [NMA] and Bücher method were used to indirectly estimate comparative progression-free survival (PFS) efficacy. A 2-state Markov model (progression-free, progressed or death) was specified. Inputs included: cost of chemotherapy, administration, adverse events (AE) management, disease monitoring; utilities for health states; and disutilities for AEs. Incremental cost effectiveness (ICER) and cost utility ratios (ICUR) were calculated for resp. PFS life years (PFS LY) and quality adjusted life years (PFS QALY) gained in base case and probabilistic sensitivity analyses (PSA). Results: NMA and Bücher indirect comparison methods yielded similar PFS hazard ratios (HR), revealing superiority of DAR+LEN+DEX over other triplets in terms of PFS (Table). Using the exponential distribution to fit PFS data, our cost effectiveness analysis indicated that all 4 triplet regimens were associated with additional PFS LY and QALY gained over LEN+DEX at additional cost. DAR+LEN+DEX was associated with the greatest PFS LY and QALY gained at the lowest relative cost, yielding superior ICER and ICUR estimates compared to other triplet regimens. Conclusions: The superior PFS efficacy of DAR+LEN+DEX is associated with positive cost effectiveness and cost utility in the setting of R/R MM. [Table: see text]
Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).
Authors: Lentzsch Suzanne , Weisel Katja C. , Mateos Maria-Victoria , Hungria Vania , Munder Markus , Nooka Ajay K. , Mark Tomer , Quach Hang , Scott Emma Catherine , Lee Je-Jung , Sonneveld Pieter , Casneuf Tineke , Chiu Christopher , Qin Xiang , Amin Himal , Thiyagarajah Piruntha , Schecter Jordan Mark , Qi Ming , Spencer Andrew 
Published: September 2018

8036 Background: Daratumumab (D), a human, CD38-targeting mAb, is well tolerated and induces deep and durable responses in patients (pts) with RRMM. We provide an update of CASTOR (NCT02136134), a multicenter, phase 3, randomized study of DVd vs Vd in RRMM. Methods: All pts received ≥1 prior line of therapy (LOT) and were administered 8 cycles (Q3W) of Vd (1.3 mg/m2 SC bortezomib on days 1, 4, 8, and 11; 20 mg PO/IV dexamethasone on days 1-2, 4-5, 8-9, and 11-12) ± D (16 mg/kg IV once weekly in Cycles 1-3, every 3 weeks for Cycles 4-8, then every 4 weeks until progression). Bortezomib-refractory pts were ineligible. Minimal residual disease (MRD) was assessed upon suspected CR and at 6 and 12 months following the first dose at sensitivities of 10–4, 10–5, and 10–6using the ClonoSEQ assay (Adaptive Biotechnologies, Seattle, WA). Results: Pts received a median (range) of 2 (1-10) prior LOTs. 66% were previously treated with bortezomib and 21% were refractory to lenalidomide in their last prior LOT. After a median follow-up of 13.0 months, PFS was significantly prolonged with DVd vs Vd (median: not reached vs 7.1 months; HR, 0.33; 95% CI, 0.26-0.43; P< 0.0001). This PFS benefit was seen regardless of number of prior LOTs received, with greatest benefit observed in 1 prior line pts (median: not reached vs 7.9 months; HR, 0.22; 95% CI, 0.14-0.34; P< 0.0001). ORR was also significantly higher for DVd vs Vd (84% vs 63%), along with ≥VGPR (62% vs 29%) and ≥CR (26% vs 10%; P< 0.0001 for all). MRD-negative rates were ≥4-fold higher at all three sensitivity thresholds with DVd vs Vd (10% vs 2% at 10–5 threshold). Pts who achieved MRD negativity demonstrated prolonged PFS compared with MRD-positive pts. 37 (15%) and 58 (24%) deaths were observed in DVd vs Vd, respectively, and follow up is ongoing. The most common grade 3/4 TEAE was thrombocytopenia (45% vs 33%). Updated efficacy and safety data will be presented. Conclusions: DVd provided significant benefits with respect to PFS, ORR, depth of response, and MRD-negative rate vs Vd. No new safety signals were reported. These data continue to support the use of DVd in RRMM pts and indicate that pts with 1 prior LOT will derive the most benefit. Clinical trial information: NCT02136134.
Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
Authors: Lakshman Arjun , Abeykoon Jithma P. , Kumar Shaji , Rajkumar S.Vincent , Kourelis Taxiarchis , Buadi Francis , Dingli David , Lacy Martha , Gonsalves Wilson I. , Dispenzieri Angela , Kyle Robert A. , Lin Yi , Go Ronald S. , Warsame Rahma M. , Hayman Suzanne R. , Russell Stephen , Leung Nelson , Gertz Morie A. , Kapoor Prashant 
Published: September 2018

8038 Background: Daratumumab-based Combination Therapies (DCT) with bortezomib (V)/ lenalidomide (R)/ pomalidomide (P) and dexamethasone (d) showed exceptional activity in RRMM in trials. Experience outside of trials since the approval of Daratumumab (D) in 2015 is limited. Methods: RRMM pts seen at Mayo Clinic, MN from 12/2015 -12/2016 were reviewed. Pts who received ≥ 1cycle of DCT were included. Time-to-event analyses were done from date of starting DCT. Common terminology criteria for adverse events v4.0 were used to grade toxicities. Results: Of 130 pts, 59% were males and median age at DCT initiation was 67 (43-93) years, ECOG performance score was ≥2 in 29%. Pts were classified as mSMART high (22%), intermediate (22%) or standard (56%) risk. Median time from diagnosis to initiation of DCT was 51.3 (5-156) months (m), and median number of prior therapies was 4 (1-14). 14% of pts were refractory to prior D monotherapy. Fifty-three (41%), 34 (26%) and 25 (19%) received DPd, DRd and DVd respectively. Eighteen (14%) pts received ‘other’ DCT. Median time to first response (≥ PR) was 3.1 m (95% CI 2.1-4.6). Overall response rate was 46%, [CR-2%, VGPR-18%, PR-26%]. Minimal response was seen in 17%, with clinical benefit rate of 62%. Median estimated follow up from initiation of DCT was 5.5 m (CI 4.2-6.1). The median duration of response was 6.1 m [CI 5.1- not reached (NR)]. Median progression free survival (PFS) was 5.5 m (CI 4.1-7.8) and median time to next therapy (TTNT) was 5.9 m (CI 4.6-9.4). Median PFS for DPd, DRd, DVd and other DCTs were 4.6 (CI 2.7-NR), 7.8 (CI 5-NR), 3.9 (CI 2.1-NR) and 3.9 (CI 2.8-8.2) m, respectively (p = 0.3). Median PFS for quadruple refractory (n = 28) MM was 2.8 m (CI 2.2-5.3) vs 5.9 m (CI 4.9-NR) for the rest (p < 0.01). Median overall survival (OS) from DCT was NR (CI 11.4-NR). Grade 3 or higher hematological toxicities were seen in 42% of pts. Other toxicities included infections (37%), fatigue (31%), infusion reactions (16%) and diarrhea (10%). Conclusions: DCT are effective in RRMM, but the PFS remains short particularly in quadruple refractory pts, reflecting the challenges encountered in managing heavily-pretreated, and often less fit patients, in routine practice.
Comparative efficacy of multiple myeloma therapies for treatment of first relapse: A systematic literature review and network meta-analysis.
Authors: Maiese Eric M , Le Moine Jean-Gabriel , Ainsworth Claire , Ahdesmäki Outi , Howe Emma 
Published: September 2018

8042 Background: Treatment for multiple myeloma (MM) in the US has undergone significant advances, with several new therapies recently FDA approved for relapse/refractory MM (RRMM), including carfilzomib+lenalidomide+dex (KRd), carfilzomib+dex (Kd), daratumumab+lenalidomide+dex (DRd), daratumumab+bortezomib+dex (DVd), ixaxomib+lenalidomide+dex (IRd), and elotuzumab+lenalidomide+dex (ERd). These new therapies have shown improvements in clinical outcomes in randomized controlled trials (RCTs). However, with few head-to-head RCTs, there is little comparative evidence to determine the most effective treatment for specific patients. A systematic literature review (SLR) and network meta-analysis (NMA) was conducted to determine the comparative efficacy (progression free survival (PFS)) of MM therapies for treating first relapse. Methods: The SLR searched MEDLINE, Embase, and the Cochrane Library for RCTs investigating the efficacy of treatments for RRMM (to August 2016). NMA was conducted on the PFS hazard ratios (HR), where available in RCTs for patients with one prior line of treatment, using Bayesian fixed effects mixed treatment comparisons. Results: Data formed two evidence networks. Network 1: RCTs with Rd; Network 2: RCTs with Vd. Analyses found DRd and DVd had the highest probability of being the best treatment (0.96 and 0.89, respectively). Compared to other MM therapies, DRd and DVd had the lowest risk of progression or death (PFS HR <1.0) (Table 1). For example, compared to KRd, DRd had a 41% (PFS HR 0.59) reduced risk of progression or death. Conclusions: This analysis provides comparative evidence among treatments where head-to-head RCTs have not been conducted. For treating first relapse, compared to other MM treatments, this analysis found that DRd and DVd had the highest probability of providing the longest progression free survival. [Table: see text]
Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study.
Authors: Owonikoko Taofeek Kunle , Dahlberg Suzanne Eleanor , Sica Gabriel , Wagner Lynne I. , Wade James Lloyd , Srkalovic Gordan , Lash Bradley Walter , Leach Joseph W. , Leal Ticiana A.B. , Aggarwal Charu , Ramalingam Suresh S. 
Published: September 2018

8505 Background: Veliparib, a potent inhibitor of Poly (ADP) ribose polymerase (PARP) enzyme potentiates standard chemotherapy against small cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib (V) with cisplatin/etoposide (CE) doublet for first-line therapy of extensive stage SCLC (ES-SCLC). Methods: Patients with ES-SCLC stratified by gender and serum LDH levels, were randomized to receive four 3-wk cycles of CE (75mg/m2 and 100 mg/m2) along with V (100mg bid on d1-7) or placebo (P). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS). Using an overall one-sided 0.10 level logrank test, this study had 88% power to detect a 37.5% reduction in the PFS hazard rate. Results: 128 eligible pts were enrolled across 33 US sites. Median age, 66 yrs; men, 52%; PS 0/1 (29%/71%). The estimated median PFS was 6.1 m vs. 5.5 m [unstratified HR: 0.75; 1-sided p = 0.06) favoring CE+V. The median OS was 10.3 m vs. 8.9 m respectively for CE+V and CE+P [stratified HR: 0.83 (80% CI 0.64-1.07); 1-sided p = 0.17]. There was a significant treatment by strata interaction in PFS: male pts with high LDH derived benefit [PFS HR of 0.34 (80% CI: 0.22-0.51)]; among pts not in this strata: PFS HR = 0.81 (80% CI: 0.60-1.09). The best objective response rate was 71.9% vs. 65.6% (2-sided p = 0.57). Salient grade ≥3 adverse events occurring in 5% of patients are summarized in the table below. Analysis of tumor samples for predictive biomarkers is planned. Conclusions: The addition of veliparib to doublet chemotherapy was associated with improved PFS in patients with extensive stage SCLC. Clinical trial information: NCT01642251. [Table: see text]
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
Authors: Stinchcombe Tom , Stahel Rolf A. , Bubendorf Lukas , Bonomi Philip , Villegas Augusto E. , Kowalski Dariusz , Baik Christina S. , Isla Dolores , De Castro Javier , Garrido Lopez Pilar , Rittmeyer Achim , Tiseo Marcello , Stanzel Sven Franz , de Haas Sanne , Lam Lisa , Lu Michael , Peters Solange 
Published: September 2018

8509 Background: T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer. We report primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts with previously treated HER2-overexpressing mNSCLC who received single-agent T-DM1. Methods: Eligible pts had HER2-overexpressing mNSCLC and were previously treated with platinum-based therapy. Pts received T-DM1 3.6 mg/kg every 3 weeks and were analyzed in 2 cohorts based on centrally determined HER2 status (immunohistochemistry [IHC]2+ vs IHC3+ [≥10% cells stained with 2+ or 3+ intensity, respectively]). HER2 amplification was assessed via ISH (HER2 gene ratio ≥2.0). The primary endpoint is objective response rate (ORR; proportion of pts with confirmed [≥4 weeks] complete or partial response per RECIST v1.1). Results: The clinical cutoff date for this analysis was Oct 26, 2016.Of 393 screened pts, 102 (27%) were IHC2+ and 29 (7%) were IHC3+. In total, 49 pts (IHC2+, n = 29; IHC3+, n = 20) received T-DM1. At cutoff, median follow-up was 16.3 (range 0.9*–22.4; * = censored observation) months. No IHC2+ pt had a response (0%, 95% CI 0–11.9); 4 IHC3+ pts had partial responses (20%, 95% CI 5.7–43.7) with a median duration of response of 7.3 (range 2.9–8.3) months. Median progression-free survival (PFS) in IHC2+ and IHC3+ pts was 2.6 (95% CI 1.4–2.8) and 2.7 (95% CI 1.4–8.3) months, respectively. At 6 months after start of study treatment, 9 pts (IHC2+, n = 4; IHC3+, n = 5) were still at risk for a PFS event. Median overall survival was 12.2 (95% CI 3.8–not estimable [NE]) months in IHC2+ pts and 12.1 (95% CI 9.3–NE) months in IHC3+ pts. Of 16 pts with HER2 amplification (IHC2+, n = 5; IHC3+, n = 11), 3 responded, all in the IHC3+ cohort (27.3%, 95% CI 6.0–61.0). Eleven pts (22%) experienced a grade 3–4 adverse event, with fatigue and dyspnea being the only events reported in > 1 pt (n = 2 each). Conclusions: This is the first study to report on the clinical activity of T-DM1 in HER2-overexpressing mNSCLC. Objective responses were observed in IHC3+ pts. Additional molecular analyses are underway to refine markers for optimal pt selection. Clinical trial information: NCT02289833.
Molecular analysis of thymic epithelial tumors (TETs): A report by The Cancer Genome Atlas (TCGA) research network.
Authors: Loehrer Patrick J. , Tsao Anne S. , Radovich Milan , Felau Ina 
Published: September 2018

8520 Background: Thymoma (T) and thymic carcinoma (TC) are the most common malignancies of the anterior mediastinum. Additionally, thymoma has an unique association with autoimmune disorders, notably myasthenia gravis (MG). Histologic classification of TETs has been largely based on the gross description of the epithelial cell appearance and the relative abundance of associated lymphocytes. A comprehensive molecular analysis of TETs has not heretofore been conducted. Methods: The TCGA Research Network conducted multi-platform analyses of 117 TETs (T = 105; TC = 10 and micronodular T = 2), which included whole-exome, transcriptome, methylome and targeted proteome analysis. Patient characteristics: median age = 60 years (range 17-84); M:F (%) = 52:48; Masaoka Stage (I-36, IIA-39, IIB-19; III-15; IVA-1; IVB-5); mg was present in 32 patients. No patient had prior therapy for metastatic disease, but 14 had prior chemotherapy and 39 had prior radiation therapy in adjuvant setting. WHO histologic classification (blinded review) revealed A = 10; A/B = 48, B1 = 12, B2 = 25, B3 = 10, micronodular T = 2 and TC = 10. Results: T has one of the lowest mutational loads of any tumor in the TCGA. A unique transcription factor, GTF2I, was the most commonly observed mutation in WHO Types A and A/B. All GTF2I mutations were exclusively at the amino acid 424 locus. This is the only tumor with this specific mutation within the entire TCGA database. HRAS, NRAS and TP53 mutations were less commonly noted among all TETs. Four distinct molecular-driven subtypes of TETs were identified that strongly correlated with the current WHO histologic classification. Increased aneuploidy and overexpression of muscle auto-antigens were associated with mg phenotype. Conclusions: Based on molecular analysis, four clusters were identified that correlated strongly with the current WHO Histologic Classification. Also identified was a unique mutation in GTF2I, which was associated with WHO Type A and A/B thymoma. This international effort represents the largest and most comprehensive molecular analysis of TETs conducted to date is expected to have important clinical and translational implications for this rare disease.
Typical bronchial NETs as a misleading biology.
Authors: Mandair Dalvinder , Diamantopoulos Leonidas-Nikolaos , Demetriou George , Laskaratos Faidon , Toumpanakis Christos , Caplin Martyn E. 
Published: September 2018

8528 Background: Bronchial Neuroendocrine tumours (NETs) are rare with an incidence of between 0.2 – 2 per 100,000 population. There has been an increase in prevalence due to increased awareness, enhanced immunohistochemistry and greater use of Computed tomography (CT). Bronchial NETs are classified according to the WHO guidelines developed in 2004 where they are graded by histological classification into ‘typical’, ‘atypical’ NETs or small and large neuroendocrine carcinoma’s (NECs). Typical NETs are regarded as being low-grade malignant however metastatic disease can still develop. Aims: We sought to determine the incidence of metastatic typical bronchial NETs, their survival and investigate the imaging and treatment used in their management. Methods: We performed a retrospective analysis of all bronchial NETs managed at our centre from 2001 to 2016. From those identified as typical NETs, we analysed clinical records in those with advanced disease (Stage IV). Results: From a total of 251 bronchial NETs, there were 147 ‘Typical’ NETs, 30(20%) of whom had advanced disease compared to 82 'Atypical' bronchial NETs of whom 55 had advanced disease (67%). The median age at diagnosis was 58 (range 24-77). In the 'Typical' NETs, 24/30 had liver metastases, 19/30 skeletal metastases, and 16 had carcinoid syndrome (CS). Functional imaging with FDG PET scan was positive in 7/10 patients and somatostatin receptor scintigraphy (SRS) positive in 16/20 and in 4/11 there was avidity with both. 20 patients were treated with somatostatin analogues predominantly for CS symptoms. 11 patients treated with peptide radiolabelled receptor targeted therapy (PRRT) with a median Time-To-Progression (TTP) of 27 months. 11 patients received chemotherapy with median TTP of 16 months with 4 patients demonstrating partial response. Conclusions: Typical bronchial NETs can lead to advanced disease in up to 20% of patients. Their behavior can be aggressive and is not predictable by histology alone. Functional imaging with both FDG and SRS may help determine the most appropriate treatment. Both PRRT and chemotherapy can be considered in progressive disease.